Alpha Geek

(8)

$10/per page/Negotiable

About Alpha Geek

Levels Tought:
University

Expertise:
Accounting,Algebra See all
Accounting,Algebra,Architecture and Design,Art & Design,Biology,Business & Finance,Calculus,Chemistry,Communications,Computer Science,Environmental science,Essay writing,Programming,Social Science,Statistics Hide all
Teaching Since: Apr 2017
Last Sign in: 346 Weeks Ago, 6 Days Ago
Questions Answered: 9562
Tutorials Posted: 9559

Education

  • bachelor in business administration
    Polytechnic State University Sanluis
    Jan-2006 - Nov-2010

  • CPA
    Polytechnic State University
    Jan-2012 - Nov-2016

Experience

  • Professor
    Harvard Square Academy (HS2)
    Mar-2012 - Present

Category > Statistics Posted 26 May 2017 My Price 5.00

Treating Motion Sickness

13.   Treating Motion Sickness The following Minitab display resulted from an experi- ment in which 10 subjects were tested for motion sickness before and after taking the drug astemizole. The Minitab data column C3 consists of differences in the number of head movements that the subjects could endure without becoming nauseous. (The dif- ferences were obtained by subtracting the “after” values from the “before” values.)

a.   Use a 0.05 significance level to test the claim that astemizole has an effect (for bet- ter or worse) on vulnerability to motion sickness. Based on the result, would you use astemizole if you were concerned about motion sickness while on a cruise ship?

b.   Instead of testing for some effect (for better or worse), suppose we want to test the claim that astemizole is effective in preventing motion sickness? What is the P- value, and what do you conclude?

95% CI for mean difference: (–48.8, 33.8)

T-Test of mean difference = 0 (vs not = 0): T-Value = –0.41 P-Value = 0.691

Answers

(8)
Status NEW Posted 26 May 2017 03:05 PM My Price 5.00

-----------

Attachments

file 1495812490-Answer.docx preview (254 words )
1-----------3.----------- ----------- T-----------rea-----------tin-----------g M-----------oti-----------on -----------Sic-----------kne-----------ss -----------The----------- fo-----------llo-----------win-----------g M-----------ini-----------tab----------- di-----------spl-----------ay -----------res-----------ult-----------ed -----------fro-----------m a-----------n e-----------xpe-----------ri------------ me-----------nt -----------in -----------whi-----------ch -----------10 -----------sub-----------jec-----------ts -----------wer-----------e t-----------est-----------ed -----------for----------- mo-----------tio-----------n s-----------ick-----------nes-----------s b-----------efo-----------re -----------and----------- af-----------ter----------- ta-----------kin-----------g t-----------he -----------dru-----------g a-----------ste-----------miz-----------ole-----------. T-----------he -----------Min-----------ita-----------b d-----------ata----------- co-----------lum-----------n C-----------3 c-----------ons-----------ist-----------s o-----------f d-----------iff-----------ere-----------nce-----------s i-----------n t-----------he -----------num-----------ber----------- of----------- he-----------ad -----------mov-----------eme-----------nts----------- th-----------at -----------the----------- su-----------bje-----------cts----------- co-----------uld----------- en-----------dur-----------e w-----------ith-----------out----------- be-----------com-----------ing----------- na-----------use-----------ous-----------. (-----------The----------- di-----------f- -----------fer-----------enc-----------es -----------wer-----------e o-----------bta-----------ine-----------d b-----------y s-----------ubt-----------rac-----------tin-----------g t-----------he -----------“-----------aft-----------er----------- -----------val-----------ues----------- fr-----------om -----------the----------- -----------be-----------for-----------e----------- v-----------alu-----------es.-----------)
Not Rated(0)
Relevent Questions